রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

polipharma industries s.r.l. - romania - imatinibum - compr. film. - 100mg - alte antineoplazice inhibitori de protein-kinaza

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - pramipexol diclorhidrat monohidrat - parkinson disease; restless legs syndrome - medicamente anti-parkinson - pramipexol accord este indicat la adulti pentru tratamentul semnelor si simptomelor bolii idiopatice parkinson, singur (fără levodopa) sau in combinatie cu levodopa, am. pe parcursul bolii, prin stadiile atunci când efectul levodopa dispare sau devine incompatibil şi fluctuaţiile de efectul terapeutic apar (sfârşitul de doză sau fluctuaţii "on-off").

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

macleods pharma uk limited - levofloxacinum - compr. film. - 250mg - chinolone antibacteriene fluorochinolone

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

macleods pharma uk limited - levofloxacinum - compr. film. - 500mg - chinolone antibacteriene fluorochinolone

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

lek pharmaceuticals d.d. - slovenia - tadalafilum - compr. film. - 20mg - alte preparate urologice (incl. antispastice) medicamente pt. trat. disfunctiei erectile

মোল্দাভিয়া - রোমানীয় - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

abbott healthcare products b.v. - dydrogesteronum - comprimate filmate - 10 mg

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

terapia sa - romania - candesartanum cilexetil - compr. - 8mg - antagonisti de angiotensina ii antagonisti de angiotensina ii

রুমানিয়া - রোমানীয় - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

terapia sa - romania - candesartanum cilexetil - compr. - 16mg - antagonisti de angiotensina ii antagonisti de angiotensina ii

ইউরোপীয় ইউনিয়ন - রোমানীয় - EMA (European Medicines Agency)

accord healthcare s.l.u. - imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. cu excepția nou diagnosticate în faza cronică a lgc, nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli. .